|Article Type:||Case study|
Pheochromocytoma (Care and treatment)
|Publication:||Name: Applied Radiology Publisher: Anderson Publishing Ltd. Audience: Academic Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2011 Anderson Publishing Ltd. ISSN: 0160-9963|
|Issue:||Date: Oct, 2011 Source Volume: 40 Source Issue: 10|
|Topic:||Event Code: 310 Science & research|
|Geographic:||Geographic Scope: United States Geographic Code: 1USA United States|
A 67-year-old white male presented with several days' history of abdominal discomfort associated with some nausea and vomiting. The patient on the day of admission had a syncopal spell while going to the bathroom. He was brought to the hospital, where ultrasound (US) of the abdomen showed a right adrenal mass that was further evaluated with a computed tomography (CT) scan.
Abdominal US revealed a large heterogeneous lesion in the right suprarenal region that arises from the adrenal gland (Figure 1). A CT scan of the abdomen revealed a 7-cm heterogeneous right suprarenal mass with attenuation similar to the liver (Figure 2).
Pheochromocytomas arise from the chromaffin cells of the adrenal gland. Anatomically on CT each adrenal gland can be seen as a linear or inverted Y- or V-shaped organ located superior, medial, and anterior to each kidney. Several imaging modalities can be used to evaluate the adrenal gland; these include CT, magnetic resonance imaging (MRI), nuclear medicine, and US.
[FIGURE 1 OMITTED]
On CT, pheochromocytomas can be seen as homogeneous or heterogeneous solid or cystic masses, possibly showing some calcification. Most pheochromocytomas have attenuation higher than 10 Hounsfield units (HU). Rarely do they contain sufficient intracellular fat to have an attenuation of < 10 HU, although some pheochromocytomas may demonstrate very high attenuation due to hemorrhage. (1) The extent of attenuation of the adrenal gland differentiates adenomas, adrenocorticocarcinomas, pheochromocytomas, and metastases. (2) Boland et al., (3) performed a meta-analysis of 10 studies to determine an optimal threshold for differentiating benign lesions from malignant. From this study, a threshold of 10 HU had 71% sensitivity and 98% specificity for characterizing adrenal masses.
On MRI, pheochromocytomas are usually seen as hypointense or isointense relative to the liver on T1-weighted spin-echo (SE) images, and they are highly intense on T2-weighted SE images. The cause of this appearance is unknown, but it likely results from the high water content in cellular homogeneous tumors or the high water content in necrotic regions. (1) Some investigators have reported that pheochromocytomas can have atypical signal characteristics on MRI in up to 25% of patients. (3) Nuclear imaging is another study used to detect lesions that are not adequately seen by a CT scan or MRI. Pheochromocytoma shows intense uptake of metaiodobenzylguanidine (miBG), thus allowing for detection of small lesions in atypical areas.
Ultrasonography is limited to the differentiation of cystic lesions from solid lesions in the adrenal gland.
Pheochromocytoma incidence could be increasing because of changes in detection methods. (4) CT and MRI have resulted in more frequent and incidental detections of adrenal masses.
Pheochromocytoma, in which symptoms are not very specific and hypertension is present in only half of patients, remains rare; it occurs in 0.1% to 0.9% of hypertensive individuals. (1) Pheochromocytoma has no race predilection, occurs with equal incidence in men and women, and commonly occurs in adults aged 20 to 40. Its clinical presentation includes headache, palpitations and diaphoresis that can lead to an episodic hypertensive crisis due to increased catecholamine production. Other associated symptoms include pallor, nausea, tremor, trembling, fatigue, anxiety, pain, and flushing. (5)
Characteristically, these symptoms are paroxysmal and may be precipitated by abdominal exertion, such as heavy lifting or performing the Valsalva maneuver. Some individuals can be asymptomatic, which explains why imaging studies are useful in diagnosing these tumors. About 10% of pheochromocytomas are malignant, bilateral, familial, and extraadrenal. Diagnosis is usually based on clinical presentation and imaging and chemical studies.
(1.) Blake MA, Kalra MK, Maher MM, et al. Pheochromocytoma: An imaging chameleon. Radiographics. 2004;24:S87-S99.
(2.) Szolar DH, Karobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: Mass and enhancement loss evaluation at delayed contrast enhanced CT. Radiology. 2005;234:479-485.
(3.) Mayo-Smith WW, Boland GW, Noto RB, et al. State-of-the-art adrenal imaging. Radiographics. 2001;21:995.
(4.) Baguet JP, Hammer L, Mazzuco TL, et al. Circumstances of discovery of phaeochromocytoma: A retrospective study of 41 consecutive patients. Eur J Endocrinol. 2004;150:681-686.
(5.) Lee TH, Slywotzky CM, Lavelle MT, Garcia RA. Best cases from the AFIP: Cystic pheochromocytoma. Radiographics. 2002;22:935-940.
Brenden Coleman, MD, Aishat Odidi, MS, and Mariel Paralitici
Prepared by Dr. Coleman, Mr. Odidi, and Ms. Paralitici while at St. Vincent's Medical Center in Bridgeport, CT.
|Gale Copyright:||Copyright 2011 Gale, Cengage Learning. All rights reserved.|